Guoying Cao
About
Guoying Cao is a scholar working on Pharmacology, Epidemiology and Molecular Medicine.
According to data from OpenAlex, Guoying Cao has authored 60 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pharmacology, 24 papers in Epidemiology and 19 papers in Molecular Medicine. Recurrent topics in Guoying Cao's work include Antibiotics Pharmacokinetics and Efficacy (31 papers), Antibiotic Resistance in Bacteria (19 papers) and Pneumonia and Respiratory Infections (17 papers). Guoying Cao is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (31 papers), Antibiotic Resistance in Bacteria (19 papers) and Pneumonia and Respiratory Infections (17 papers). Guoying Cao collaborates with scholars based in China, Australia and Brazil. Guoying Cao's co-authors include Xiaojie Wu, Jicheng Yu, Jing Zhang, Jian Li, Roger L. Nation, Xin Hu, Alexandre Prehn Zavascki, Beining Guo, Aixin Shi and Wei Xue and has published in prestigious journals such as Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy and Journal of Ethnopharmacology.
In The Last Decade
Guoying Cao
58 papers receiving 1.1k citations
Peers
Guoying Cao
Kayo Ikeda Japan
Michael S. Schwartz United States
Yingmei Liu China
Kelly Pittman United States
Hugues Chanteux Belgium
Lei Ma United States
Taijun Yin United States
Min Hao China
Ravindra Yeole India
Guanyang Lin China
Citations per year, relative to Guoying Cao Guoying Cao (= 1×)
peers
Kayo Ikeda
Countries citing papers authored by Guoying Cao
Since
Specialization
Citations
This map shows the geographic impact of Guoying Cao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guoying Cao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guoying Cao more than expected).
Fields of papers citing papers by Guoying Cao
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Guoying Cao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guoying Cao. The network helps show where Guoying Cao may publish in the future.
Co-authorship network of co-authors of Guoying Cao
This figure shows the co-authorship network connecting the top 25 collaborators of Guoying Cao. A scholar is included among the top collaborators of Guoying Cao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guoying Cao. Guoying Cao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Li, Yi, Xu Zhu, Jicheng Yu, et al.. (2024). Lefamulin dosing optimization using population pharmacokinetic and pharmacokinetic/pharmacodynamic assessment in Chinese patients with community-acquired bacterial pneumonia. Frontiers in Pharmacology. 15. 1456741–1456741.
2.
Zhang, Jing, Guoying Cao, Yong Huo, et al.. (2024). A Randomized, Parallel, Open‐Label, Single‐Dose and Multiple‐Dose Clinical Trial to Investigate the Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Obicetrapib in Healthy Participants in China. The Journal of Clinical Pharmacology. 65(1). 96–107.
3.
Wu, Junzhen, Qiong Wei, Yi Jin, et al.. (2024). Safety, tolerability, and pharmacokinetics of a novel anti-influenza agent ZX-7101A tablets in healthy chinese participants: A first-in-human phase I clinical study. International Journal of Antimicrobial Agents. 65(1). 107381–107381.
4.
Li, Yi, Jufang Wu, Jicheng Yu, et al.. (2023). Population pharmacokinetics and exposure-safety of lipophilic conjugates prodrug DP-VPA in healthy Chinese subjects for dose regime exploring. European Journal of Pharmaceutics and Biopharmaceutics. 188. 153–160.
5.
Li, Yi, Kaoru Toyama, Hitoshi Ishizuka, et al.. (2023). Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study. Advances in Therapy. 40(4). 1628–1643.
6.
He, Jinjie, Qingyang Ma, Jicheng Yu, et al.. (2023). Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study. Expert Opinion on Investigational Drugs. 32(7). 669–675.
7.
Hu, Yingying, Qiong Wei, Xinyi Yang, et al.. (2023). Pharmacokinetic, Pharmacokinetic/Pharmacodynamic, and Safety Investigations of Lefamulin in Healthy Chinese Subjects. Antibiotics. 12(9). 1391–1391.
8.
Zeng, Xiaofeng, et al.. (2022). Comparative assessment of pharmacokinetic parameters between HS016, an adalimumab biosimilar, and adalimumab (Humira®) in healthy subjects and ankylosing spondylitis patients: Population pharmacokinetic modeling. Advances in Clinical and Experimental Medicine. 31(5). 499–509.
9.
Zhang, Jing, Weiguo Wan, Liyan Miao, et al.. (2020). Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study. Rheumatology and Therapy. 7(1). 191–200.
10.
Li, Li, Hailan Wu, Yuancheng Chen, et al.. (2020). Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients. Clinical Therapeutics. 42(5). 818–829.
11.
He, Jinjie, Guoying Cao, Jicheng Yu, et al.. (2020). Safety, Tolerability and Pharmacokinetics of Single Ascending and Multiple Oral Doses of Tegoprazan in Healthy Chinese Subjects. Clinical Drug Investigation. 41(1). 89–97.
12.
Li, Yi, Yaxin Fan, Jing Zhang, et al.. (2019). Determination of DP‐VPA and its active metabolite, VPA, in human plasma, urine, and feces by UPLC–MS/MS: A clinical pharmacokinetics and excretion study. Drug Testing and Analysis. 11(7). 1035–1047.
13.
Guo, Beining, Jing Zhang, Yi Li, et al.. (2018). Determination of the sulfate and glucuronide conjugates of levornidazole in human plasma and urine, and levornidazole and its five metabolites in human feces by high performance liquid chromatography–tandem mass spectrometry. Journal of Chromatography B. 1081-1082. 87–100.
14.
Guo, Beining, Xiaojie Wu, Jicheng Yu, et al.. (2017). Clinical Pharmacokinetics of Levornidazole in Elderly Subjects and Dosing Regimen Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis. Clinical Therapeutics. 39(7). 1336–1346.
15.
Fan, Yaxin, Xiaojie Wu, Miao Zhao, et al.. (2016). Rapid and Simultaneous Quantitation of Amoxicillin and Clavulanic Acid in Human Plasma and Urine by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry and Its Application to a Pharmacokinetic Study. Analytical Sciences. 32(12). 1269–1276.
16.
Cao, Guoying, Bei Yan, Wei Xue, et al.. (2015). Pharmacokinetics, safety, and tolerability of single and multiple-doses of pinocembrin injection administered intravenously in healthy subjects. Journal of Ethnopharmacology. 168. 31–36.
17.
Li, Min, Aixin Shi, Wei Xue, et al.. (2014). Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects. Journal of Ethnopharmacology. 156. 210–215.
18.
Cao, Guoying, Anima Poudyal, Timo Vaara, et al.. (2009). Pharmacokinetics of novel antimicrobial cationic peptides NAB 7061 and NAB 739 in rats following intravenous administration. Journal of Antimicrobial Chemotherapy. 64(5). 1067–1070.
19.
Zhang, Jing, Xin Xie, Xin Zhou, et al.. (2009). Permeability and Concentration of Levofloxacin in Epithelial Lining Fluid in Patients With Lower Respiratory Tract Infections. The Journal of Clinical Pharmacology. 50(8). 922–928.
20.
Zhang, Jing, Xiaojie Wu, Guoying Cao, et al.. (2009). Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. Journal of Infection and Chemotherapy. 15(5). 293–300.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Kayo Ikeda Breakdown of academic impact, for papers by Michael S. Schwartz Breakdown of academic impact, for papers by Yingmei Liu Breakdown of academic impact, for papers by Kelly Pittman Breakdown of academic impact, for papers by Hugues Chanteux Breakdown of academic impact, for papers by Lei Ma Breakdown of academic impact, for papers by Taijun Yin Breakdown of academic impact, for papers by Min Hao Breakdown of academic impact, for papers by Ravindra Yeole Breakdown of academic impact, for papers by Guanyang Lin